On November 9, 2020 APEIRON Biologics AG, a privately-held biotech company developing breakthrough therapies to treat cancer and respiratory conditions, reported that it has selected Domainex Ltd to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery (Press release, Apeiron Biologics, NOV 9, 2020, View Source [SID1234570288]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Domainex, a leading integrated drug discovery research service partner, will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development. To date, Domainex has successfully provided APEIRON with its expertise in hit identification, both fragment-based and virtual screening, by establishing and deploying a suite of biophysical assays against variants of the E3 ligase Cbl-b and other members of this target class, to determine the binding affinity, mechanism and selectivity of promising compounds. The partnership will now progress into its next stage, with Domainex providing lead optimisation services.
Dr. Tom Mander, CEO of Domainex Ltd, said: "We are delighted to move into this new phase of our partnership with APEIRON Biologics to support the discovery and development of new medicines to treat cancer. Our multi-disciplinary team of scientists has been successful at generating multiple compound series with promising properties. Their commitment through seven-day a week operations and implementation of shift-patterns has enabled us to continue to progress client-sponsored projects throughout the COVID-19 pandemic whilst maintaining social distancing at our state-of the art Medicines Research Centre. We look forward to continuing our journey of discovery with APEIRON."
Peter Llewellyn-Davies, CEO of APEIRON Biologics AG, commented: "Finding the right research partner for the development of our highly innovative immune-oncology therapeutics is essential for fast, efficient and ultimately successful results. We are delighted to expand our partnership with Domainex for our Cbl-b targeted APN431 project and help us to quickly move to the next stage of its development. Domainex provides deep know-how in state-of-the-art structure based medicinal chemistry and assay development to help us achieve our ambitious goals. With our small molecule program APN431 we have an additnal approach to target Cbl-b, next to our autologous cell therapy program APN401, which is currently in clinical Phase 1 development."